Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.42 USD
-0.03 (-0.87%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $3.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for ANIXA BIOSCIENCES INC falls in the month of October.
All items in Millions except Per Share data.
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 30 | 36 | 9 | 6 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 0 | 0 | 0 |
Total Current Assets | 25 | 30 | 36 | 9 | 6 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 26 | 30 | 36 | 9 | 6 |
Liabilities & Shareholders Equity | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 1 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 1 | 1 | 1 |
Shareholders Equity | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 252 | 247 | 240 | 200 | 187 |
Retained Earnings | -228 | -218 | -205 | -192 | -182 |
Other Equity | -1 | -1 | -1 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 23 | 28 | 35 | 8 | 5 |
Total Liabilities & Shareholder's Equity | 26 | 30 | 36 | 9 | 6 |
Total Common Equity | 23 | 28 | 35 | 8 | 5 |
Shares Outstanding | 31.00 | 30.60 | 29.90 | 23.70 | 20.20 |
Book Value Per Share | 0.75 | 0.92 | 1.16 | 0.35 | 0.24 |
Fiscal Year End for ANIXA BIOSCIENCES INC falls in the month of October.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 23 | 24 | 24 | 26 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 1 |
Total Current Assets | 23 | 24 | 25 | 25 | 26 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 23 | 24 | 25 | 26 | 27 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 2 | 2 | 2 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 259 | 258 | 256 | 252 | 251 |
Retained Earnings | -238 | -235 | -231 | -228 | -226 |
Other Equity | -1 | -1 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 21 | 23 | 24 | 23 | 25 |
Total Liabilities & Shareholder's Equity | 23 | 24 | 25 | 26 | 27 |
Total Common Equity | 21 | 23 | 24 | 23 | 25 |
Shares Outstanding | 32.00 | 31.90 | 31.70 | 31.00 | 30.90 |
Book Value Per Share | 0.65 | 0.71 | 0.74 | 0.75 | 0.80 |